ApoB and Lp(a) blood tests: ranges, what they mean and what lowers them
Reviewed 15 sourcesPublished by PepVault
What ApoB and Lp(a) measure, the cut-offs each guideline sets (ESC/EAS, NLA, ACC/AHA), nmol/L vs mg/dL, why Lp(a) is tested once, and what lowers each.

- Last reviewed
- Sources
- 15
- Questions
- 7
- Compounds
- 1
The short answer
ApoB counts the particles that carry cholesterol into artery walls; Lp(a) is one inherited kind of those particles. Ask for ApoB with a lipid panel and Lp(a) once in adulthood. The NLA's ApoB lines are 90 mg/dL at intermediate risk, 70 at high and 60 at very high. Lp(a) under 75 nmol/L is low; 125 nmol/L (50 mg/dL) or more is high.
- ApoB is a particle count: one ApoB protein sits on every particle that can lodge in an artery wall.
- Lp(a) is more than 90% set by your genes, so one test in adulthood is usually enough.
- High Lp(a) is common: about one person in five has a raised level.
- ApoB falls with today's drugs; the first outcome trial of an Lp(a) drug held Lp(a) at about a quarter of placebo's level but did not cut heart events.
Evidence: Strong for both tests as risk markers: guidelines from the ESC/EAS, NLA and ACC/AHA built on genetic studies of hundreds of thousands of people and large randomized trials. Lowering ApoB cuts heart events in trials; lowering Lp(a) itself has not yet shown that.

What does an ApoB test measure?
ApoB (apolipoprotein B) is the protein shell on every particle that can carry cholesterol into an artery wall: LDL, the smaller remnant particles, VLDL and Lp(a). Each particle carries exactly one, so an ApoB test is a head count of those particles1. A standard LDL cholesterol result tells you how much cholesterol the particles hold, not how many there are.
The count is what matters. A genetic study of 654,783 people compared two sets of gene variants, one that lowers triglycerides and one that lowers LDL cholesterol. This kind of study is called Mendelian randomization: nature hands out the variants at random, like a lifelong trial. Per 10 mg/dL lower ApoB, both sets carried the same lower risk of coronary heart disease, about 23% (odds ratio 0.77). Once ApoB was accounted for, triglycerides and LDL cholesterol added nothing2. The authors' reading: the benefit of lowering either one follows the change in ApoB.
That is why the National Lipid Association (NLA) calls ApoB better than LDL cholesterol for judging risk, both before and during treatment. The two can disagree in one person, and when they do, risk generally follows ApoB1.

What is Lp(a), and why is it different?
Lp(a), said "L-P-little-a", is an LDL-like particle with an extra protein, apo(a), wound around it. It counts in your ApoB too, since it carries one. What sets it apart is where its level comes from: more than 90% is set by genes, more than any other blood fat, and adult levels are usually reached by about age 53.
Large genetic and population studies show high Lp(a) causes artery disease and is linked to a narrowing aortic valve, and the risk climbs with the level, even when LDL cholesterol is very low3. It is common: about one person in five has a raised level, yet few are ever measured4.
Commonly reported: the first Lp(a) result is the surprise on an otherwise tidy panel, high while LDL sits in range. Many people also find ApoB and Lp(a) are not on the standard lipid panel and have to be asked for by name.
What is a good ApoB number?
Each guideline ties its ApoB line to your overall risk. Very high risk means, in short, you already have artery disease or a similar burden; high and moderate risk come from your age, blood pressure, diabetes, smoking and family history. The European guideline (ESC/EAS, 2019) sets ApoB goals5; its 2025 update kept the 2019 cholesterol goals for every risk group6. The NLA's 2024 consensus suggests ApoB lines at which to consider starting or stepping up treatment, matched to US LDL lines1.
| Your risk | ESC/EAS goal (2019) | NLA treatment line (2024) | LDL cholesterol goal, ACC/AHA 2026 |
|---|---|---|---|
| Very high | Under 65 mg/dL | 60 mg/dL | Under 55 mg/dL |
| High | Under 80 mg/dL | 70 mg/dL | Under 70 mg/dL |
| Moderate, or borderline to intermediate | Under 100 mg/dL | 90 mg/dL | Under 100 mg/dL |
For scale: the median untreated US adult sits at 90 mg/dL, and 130 mg/dL is about the 90th percentile. The NLA treats ApoB of 130 or more as a risk-enhancing factor worth a conversation about treatment1. Some labs print ApoB in g/L; divide mg/dL by 100, so 90 mg/dL is 0.9 g/L.
The 2026 US guideline (ACC/AHA) keeps LDL cholesterol as the main goal and brings back numeric goals for it. Once LDL and non-HDL goals are met, it uses ApoB to find the risk that is left, in people with type 2 diabetes, high triglycerides, known heart disease or cardiovascular-kidney-metabolic syndrome, where ApoB may track risk better than LDL78.
What Lp(a) level is high, and is it nmol/L or mg/dL?
Labs report Lp(a) two ways. nmol/L counts particles; mg/dL weighs them. The apo(a) protein comes in many sizes, so particles weigh different amounts from one person to the next, and no single factor converts one unit into the other; the European consensus calls any factor a best guess3. The 2025 European update prefers nmol/L6. Compare a result only with the cut-off in its own unit.
| Guideline | Low | High | Very high |
|---|---|---|---|
| EAS consensus 2022 | Under 30 mg/dL (under 75 nmol/L) rules risk out | Over 50 mg/dL (over 125 nmol/L) rules risk in | Risk keeps rising with the level |
| NLA 2024 | Under 75 nmol/L (30 mg/dL) | 125 nmol/L (50 mg/dL) or more; 75 to 125 is intermediate | Not set |
| ACC/AHA 2026 | — | 125 nmol/L or 50 mg/dL or more: about 1.4 times the long-term heart attack and stroke risk | 250 nmol/L: at least twice the risk |
| ESC/EAS 2019 and 2025 | — | 2025: over 50 mg/dL (105 nmol/L or more) can move someone up a risk category | 2019: 180 mg/dL (430 nmol/L) or more carries about the lifetime risk of inherited high cholesterol (familial hypercholesterolaemia) |
The guidelines agree on the shape: under 75 nmol/L is low, the European guideline starts counting it from 105, the US and EAS lines call 125 and up high, and the higher it goes the more it weighs34568.
How do you get tested, and how often?
- Ask for ApoB by name with your next lipid panel; it is a routine blood draw.
- Ask for Lp(a) once. The NLA, the EAS and the 2026 US guideline all say to measure it at least once in every adult; the European update says it should be considered at least once in every adult's lifetime4386.
- Note the unit on the report, nmol/L or mg/dL, before you compare it with any cut-off.
- Repeat ApoB at the same lab where you can when you change diet, weight or treatment: ApoB tests usually vary by about 5 to 6%, so a small change can be noise1.
- Skip repeat Lp(a) tests in most cases: lifestyle barely moves it8. One exception the European update names is a second test after menopause, when women's levels tend to rise, if the first was borderline63.
- If your Lp(a) is high, tell your parents, siblings and children: the EAS and NLA back testing close relatives, since it runs in families34.
- Write down each result with its date, value, unit and lab.
PepVault's bloodwork log has ApoB built in: each result sits on a range bar and lines up with your earlier panels as a trend. Log it in PepVault
Lp(a) goes in as a custom marker, with the unit and range your lab prints. Log it in PepVault
What lowers ApoB?
ApoB responds to treatment, and the biggest trials show what that buys. In FOURIER, 27,564 people with artery disease already on a statin added evolocumab, a PCSK9-blocking injection. LDL cholesterol fell 59%, to a median 30 mg/dL, and over 2.2 years the main composite (heart deaths, heart attacks, strokes, unstable-angina admissions and artery-opening procedures) dropped from 11.3% to 9.8% (hazard ratio 0.85)9. Median ApoB on evolocumab was 38 mg/dL1.
- Ezetimibe, a pill that blocks cholesterol uptake in the gut: added to a statin in IMPROVE-IT, it cut ApoB by another 15%, to a median 67 mg/dL1.
- Retatrutide, a weekly GLP-1, GIP and glucagon injection: in a phase 2 trial in obesity without diabetes, 12 mg lowered ApoB by 24.2% over 48 weeks, against 6.8% on placebo; with type 2 diabetes, 8 mg lowered it by 21.4% at 36 weeks, against 0.2% on placebo10. Retatrutide is investigational, and these are post hoc results.
- The genetic data point the same way: each 10 mg/dL off ApoB carried the same risk cut, whether triglycerides or LDL did the moving2.
Whether to start a statin, ezetimibe or a PCSK9 drug, and which goal fits you, is a decision for your doctor, who weighs your whole risk.
Can you lower Lp(a)?
Not much with lifestyle: the EAS finds diet and exercise have minimal effect, apart from a 10 to 15% drop on a low-carbohydrate, high-fat diet. Statins leave it flat or nudge it up slightly. PCSK9 drugs lower it 15 to 30%, and hormone therapy after menopause about 25%3. In FOURIER, evolocumab cut Lp(a) by a median 26.9%, and people who started above the median Lp(a) tended to get the bigger benefit: 23% fewer coronary events, against 7% for those below it11.
The drugs built for Lp(a) cut it far deeper. Olpasiran, an injection that cuts the liver's production of Lp(a), lowered Lp(a) by 97 to 101% against placebo at 36 weeks on its higher doses12. The first outcome result arrived in November 2026, and it was a miss. In Lp(a)HORIZON, the first outcome trial built for Lp(a), 8,322 people with heart disease and an Lp(a) of at least 70 mg/dL took monthly pelacarsen or placebo for a median 4.7 years. From a median 236 nmol/L, Lp(a) at one year was 64.4 on pelacarsen against 233.4 on placebo, yet major heart events were the same: 12.3% against 12.1% (hazard ratio 1.02)13.
That leaves olpasiran's and lepodisiran's outcome trials, with main results expected in 2028 and 20291415. Until one shows fewer events, the guidelines' answer to a high Lp(a) is the same: manage every other risk factor earlier and harder, starting with LDL cholesterol34.
When to get help An Lp(a) of 250 nmol/L or more, an ApoB of 130 mg/dL or more, or a parent or sibling with an early heart attack is a good reason to book time with your doctor18.
Sources
- Soffer DE et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024. PubMed 39256087
- Ference BA et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019. PubMed 30694319
- Kronenberg F et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022. PubMed 36036785
- Koschinsky ML et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024. PubMed 38565461
- Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020. PubMed 31504418
- 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025. PubMed 40878289
- Blumenthal RS et al. 2026 ACC/AHA/multisociety Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. PubMed 41824590
- American College of Cardiology. ACC/AHA issue updated guideline for managing lipids, cholesterol (press release on the guideline's key recommendations). March 13, 2026. acc.org
- Sabatine MS et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). N Engl J Med. 2017. PubMed 28304224
- Ruotolo G et al. Retatrutide-associated improvements in cardiovascular risk biomarkers in adults with obesity with or without type 2 diabetes. Diabetes Obes Metab. 2026. PubMed 42608321
- O'Donoghue ML et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019. PubMed 30586750
- O'Donoghue ML et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease (OCEAN(a)-DOSE). N Engl J Med. 2022. PubMed 36342163
- Cho L et al. Pelacarsen and cardiovascular outcomes in patients with high lipoprotein(a) (Lp(a)HORIZON). N Engl J Med. 2026. PubMed 43001734
- ClinicalTrials.gov NCT05581303. Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial. Amgen. clinicaltrials.gov
- ClinicalTrials.gov NCT06292013. A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a). Eli Lilly and Company. clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.